Symphony Technology Group Buys ImpactRx

Private equity firm Symphony Technology Partners has acquired a majority stake in ImpactRx, a developer of a subscription database for pharmaceutical companies. The company, based in Mr. Laurel, N.J., had recently closed a $1.2 million Series E round in January, and was backed by roughly $36 million from investors including Mediphase Venture Partners, 3i Group, Oxford Bioscience Partners and Merck Capital Ventures. Financial terms of the acquisition by Symphony Technology Group were not released.

North AmericaUSBriefs